2.42
前日終値:
$2.47
開ける:
$2.41
24時間の取引高:
119.30K
Relative Volume:
0.11
時価総額:
$100.97M
収益:
-
当期純損益:
$-82.60M
株価収益率:
-1.1748
EPS:
-2.06
ネットキャッシュフロー:
$-48.61M
1週間 パフォーマンス:
-19.80%
1か月 パフォーマンス:
+9.95%
6か月 パフォーマンス:
-30.77%
1年 パフォーマンス:
-29.57%
Vigil Neuroscience Inc Stock (VIGL) Company Profile
VIGL を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
VIGL
Vigil Neuroscience Inc
|
2.42 | 100.97M | 0 | -82.60M | -48.61M | -2.06 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-04 | 開始されました | William Blair | Outperform |
2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
2023-10-18 | 開始されました | JMP Securities | Mkt Outperform |
2023-03-31 | 開始されました | Mizuho | Buy |
2022-09-16 | 開始されました | Wedbush | Outperform |
2022-08-29 | 開始されました | H.C. Wainwright | Buy |
2022-02-01 | 開始されました | Guggenheim | Buy |
2022-02-01 | 開始されました | Jefferies | Buy |
2022-02-01 | 開始されました | Morgan Stanley | Equal-Weight |
2022-02-01 | 開始されました | Stifel | Buy |
すべてを表示
Vigil Neuroscience Inc (VIGL) 最新ニュース
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - PR Newswire
What Did We Find About Insider Trading At Vigil Neuroscience Inc (NASDAQ: VIGL)? - Stocks Register
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial - MSN
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 145.8% - MarketBeat
abrdn plc Purchases 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
VIGLVigil Neuroscience, Inc. Latest Stock News & Market Updates - StockTitan
VIGL Stock Update: Vigil Neuroscience Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
The Attractiveness of Investing In Vigil Neuroscience Inc (VIGL) is Growing - Knox Daily
Are Vigil Neuroscience Inc’shares a good deal? - US Post News
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Neurodegenerative Disease Pioneer Vigil to Reveal Latest Developments at Major Biotech Conference - StockTitan
Vigil Neuroscience Reports Positive Data from Phase 1 Clinical Trial on Potential Alzheimer’s Treatment - Defense World
Vigil Neuroscience shares rise on positive Alzheimer's trial data - MSN
Guggenheim Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Vigil Neuroscience's (VIGL) Buy Rating Reiterated at Guggenheim - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World
HC Wainwright Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - MarketBeat
Vigil moves into Phase II with Alzheimer's pill - The Pharma Letter
Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update) - MSN
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial By Investing.com - Investing.com South Africa
Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments - Seeking Alpha
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3 - AOL
Vigil Neuroscience stock up on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience stock gains on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience Announces Positive Phase 1 Trial Results - TipRanks
Vigil Neuroscience shares rise on positive Alzheimer's trial data By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Vigil Neuroscience Reports Positive Data from its Phase 1 - GlobeNewswire
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for - The Bakersfield Californian
Vigil's Alzheimer's Drug Shows Promising Phase 1 Results with 50% Brain Biomarker Reduction - StockTitan
Vigil Neuroscience, Inc. Reports Positive Data from its Phase 1 Clinical Trial Evaluating Vv-3927 for the Potential Treatment of Alzheimer's Disease - Marketscreener.com
Glimpse Group Inc (NASDAQ: VRAR) Down -21.05% This Year: What To Expect Next - Stocks Register
Them too in TREM2: Street keeping AD Vigil - BioWorld Online
Q4 Earnings Forecast for VIGL Issued By William Blair - Defense World
Q4 Earnings Estimate for VIGL Issued By William Blair - MarketBeat
Geode Capital Management LLC Raises Position in Ballard Power Systems Inc. (NASDAQ:BLDP) - Defense World
Geode Capital Management LLC Grows Stake in Kewaunee Scientific Co. (NASDAQ:KEQU) - Defense World
Geode Capital Management LLC Purchases 66,712 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones - The Manila Times
CarGurus to Present at 27th Annual Needham Growth Conference - The Manila Times
Vigil Neuroscience Lands $40M Sanofi Investment, FDA Signals Path for Accelerated Approval - StockTitan
Vigil Neuroscience stock hits 52-week low at $1.51 By Investing.com - Investing.com South Africa
Vigil Neuroscience stock hits 52-week low at $1.51 - Investing.com
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Decrease in Short Interest - MarketBeat
Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares By Investing.com - Investing.com South Africa
Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares - Investing.com India
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Purchases 12,000 Shares - MarketBeat
Vigil Neuroscience Inc (VIGL) 財務データ
収益
当期純利益
現金流量
EPS
Vigil Neuroscience Inc (VIGL) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Magovcevic-Liebisch Ivana | President and CEO |
Dec 19 '24 |
Buy |
1.68 |
5,000 |
8,400 |
222,687 |
Magovcevic-Liebisch Ivana | President and CEO |
Dec 18 '24 |
Buy |
1.67 |
5,000 |
8,350 |
217,687 |
Magovcevic-Liebisch Ivana | President and CEO |
Dec 05 '24 |
Buy |
2.34 |
5,000 |
11,700 |
212,687 |
大文字化:
|
ボリューム (24 時間):